November 2021

Swiss RTS television reportage for T.T.C.

Swiss national television RTS came to CUTISS recently to find out about the denovoSkin, and to hear from our CIO Vincent about the promising potential of automation to scale up skin tissue bioengineering. The CUTISS segment was broadcast as part of RTS’s business program T.T.C. (Toutes taxes comprises) and is available on playback (in French) using the link below. Newsroom LInk to program

Swiss RTS television reportage for T.T.C. Read More »

RSI La 1, Come va? episode on skin

The Swiss national television channel RSI La 1 recently came to our offices to take a closer look at our work to develop denovoSkin, the personalized, bioengineered skin graft for children and adults suffering from large skin defects, such as severe burns. The interview with Daniela Marino was part of their monthly program Come va?, the popular science show exploring current health and medical topics, and this month’s episode focused on our body’s largest organ: skin. The episode is available on playback (in Italian) with the link below. Newsroom LInk to episode

RSI La 1, Come va? episode on skin Read More »

Journal of Wound Care: The future of bioengineering personalized skin

As part of the journal’s “Innovations in wound care” section, the latest edition features a guest editorial by our CEO Daniela Marino and CIO Vincent Ronfard. When patients suffer from large and severe skin injuries affecting more than 50% of the body, such as burns, then the current standard of care – autografting – presents real challenges. New approaches to bioengineering skin could change the paradigm for large burn treatment. But even so, other challenges remain, such as mainly manual, time-consuming and costly production. Our authors put forward that automation is the answer, meeting three key objectives: reduction in manufacturing time, improved skin graft quality and safety, and decreased costs. CUTISS has developed the denovoSkin, an autologous bioengineered dermo-epidermal skin graft, intended to provide permanent skin coverage with minimal scarring. It is currently in phase II clinical trials, and is manufactured manually in a fully equipped cleanroom by highly skilled personnel. The future of denovoSkin is the automation of its manufacturing process, and CUTISS has already produced groundbreaking research and development grade prototypes for the automated production of denovoSkin. At this moment, CUTISS remains the industry pioneer in the automation of bioengineered skin manufacturing. Read the ARTICLE for further insights on the challenges and opportunities in regenerative medicine. Newsroom LInk to FULL Article

Journal of Wound Care: The future of bioengineering personalized skin Read More »

Scroll to Top


Would you like to contact us as a journalist?


This website uses cookies to ensure you get the best experience on our website.